Brief: Kezar Life Sciences Ceases Enrollment, Dosing In Mid-Stage Trial Of Zetomipzomib

Kezar Life Sciences

30/09/2024 13:53

Sept 30 (Reuters) - Kezar Life Sciences Inc  KZR.O :
    * KEZAR LIFE SCIENCES ANNOUNCES CESSATION OF ENROLLMENT AND
DOSING
IN THE PHASE 2B PALIZADE TRIAL OF ZETOMIPZOMIB IN ACTIVE LUPUS
NEPHRITIS PATIENTS
    * KEZAR LIFE SCIENCES INC - HALTS ENROLLMENT AND DOSING IN
PHASE
2B PALIZADE TRIAL
    * KEZAR LIFE SCIENCES INC - IDMC RECOMMENDS SUSPENSION AFTER
FOUR
FATAL SERIOUS ADVERSE EVENTS
    * KEZAR LIFE SCIENCES INC - IDMC FINDS COMMON PATTERN IN
FATALITIES AND NON-FATAL SAES
    * KEZAR LIFE SCIENCES INC - NOTIFIES FDA AND EUROPEAN
MEDICINES
AGENCY OF DECISION
    * KEZAR LIFE SCIENCES INC - NO FORMAL CLINICAL HOLD ISSUED
YET,
KEZAR TO REVIEW IF RECEIVED

Source text for Eikon:  urn:newsml:reuters.com:*:nBw3YtCDa
Further company coverage:  KZR.O 

 ((Reuters.Briefs@thomsonreuters.com;))